A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Trial Profile

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs CK 301 (Primary)
  • Indications Head and neck cancer; Hodgkin's disease; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Checkpoint Therapeutics
  • Most Recent Events

    • 06 Jul 2017 Status changed from planning to not yet recruiting.
    • 10 Apr 2017 New trial record
    • 04 Apr 2017 According to a Checkpoint Therapeutics media release, this study is planned to commence in the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top